Logo

PLUR

Pluri Inc.

PLUR

Pluri Inc. • NASDAQ
$3.79 ▼ -0.26% (-0.01)
Market Cap $27.31 M
52w High $7.13
52w Low $3.22
Dividend Yield 0%
P/E -1.21
Volume 7.65K
Outstanding Shares 7.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $316K ▼ $6.495M ▼ $-6.132M ▲ -1.941K% ▼ $-0.65 ▲ $-5.773M ▲
Q4-2025 $398K ▼ $6.828M ▲ $-7.598M ▼ -1.909K% ▼ $-0.96 ▲ $-7.43M ▼
Q3-2025 $427K ▲ $5.536M ▲ $-6.147M ▼ -1.44K% ▲ $-1.14 ▼ $-6.051M ▼
Q2-2025 $185K ▼ $5.068M ▼ $-2.956M ▲ -1.598K% ▲ $-0.53 ▲ $-2.831M ▲
Q1-2025 $326K $5.398M $-5.882M -1.804K% $-1.12 $-5.754M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $15.056M ▼ $33.672M ▼ $39.319M ▼ $-11.36M ▼
Q4-2025 $20.613M ▼ $38.683M ▲ $39.548M ▲ $-6.842M ▼
Q3-2025 $26.273M ▲ $37.407M ▲ $36.924M ▲ $-4.474M ▲
Q2-2025 $21.313M ▼ $30.861M ▼ $33.778M ▼ $-8.028M ▼
Q1-2025 $26.024M $35.442M $35.505M $-5.283M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-6.132M ▲ $-5.428M ▼ $3.85M ▲ $0 ▲ $-1.6M ▲ $-5.544M ▲
Q4-2025 $-7.769M ▼ $-5.216M ▼ $3.028M ▲ $-435K ▼ $-2.496M ▼ $-5.937M ▼
Q3-2025 $-6.489M ▼ $-4.303M ▲ $-4.232M ▼ $9.968M ▲ $1.416M ▼ $-4.88M ▼
Q2-2025 $-3.11M ▲ $-4.628M ▼ $8.645M ▲ $0 $4.074M ▲ $-4.74M ▼
Q1-2025 $-6.036M $-4.064M $585K $0 $-3.455M $-4.272M

Five-Year Company Overview

Income Statement

Income Statement Pluri is still very much a development‑stage company: it reports essentially no revenue and has done so for several years. All activity is focused on research, early business building, and overhead, which together generate ongoing operating and net losses. Those losses appear to be gradually shrinking, but the business remains fully dependent on outside capital rather than on internally generated income. In plain terms, the science and platforms are being built, but commercial payback has not yet started to show up in the financials.

Balance Sheet

Balance Sheet The balance sheet is small and relatively fragile. Asset levels are modest, the cash cushion is limited, and there is a noticeable layer of debt. Equity has recently slipped into negative territory, which signals accumulated losses have overtaken the company’s capital base. That combination typically points to financial strain and a need for continued access to funding, whether through new equity, new debt, or partnerships, and it can also leave little room to absorb setbacks.

Cash Flow

Cash Flow Cash is consistently flowing out of the business rather than in. Operating cash flow has been negative for years, reflecting spending on R&D, staff, and operations without offsetting revenue. Free cash flow mirrors this pattern, and there is virtually no investment in heavy physical assets, underscoring that most spending is on people, labs, and intellectual property. This is typical for an early‑stage biotech, but it means the company likely needs periodic capital raises to sustain its plans.

Competitive Edge

Competitive Edge Pluri’s competitive position rests on its proprietary 3D cell expansion platform, large patent portfolio, and in‑house manufacturing know‑how. It is trying to turn this into a broad platform that serves several sectors at once: regenerative medicine, cultivated foods, and agricultural biotech, plus contract manufacturing for other cell and gene therapy players. These are attractive, fast‑moving arenas but also very competitive, with many larger, better‑funded rivals and significant regulatory and technical hurdles. Pluri’s breadth of applications and partnerships is a strength, but its lack of commercial revenue so far means its competitive position is still more potential than proven in the marketplace.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Pluri. The company is advancing placenta‑based cell therapies, an immuno‑oncology platform using MAIT cells, and several cell‑based food and agriculture ventures, including cultivated meat, cacao, and coffee. It is also monetizing its manufacturing expertise through CDMO services for third parties. This is a highly ambitious, multi‑pronged R&D agenda that could create multiple revenue streams if programs succeed. At the same time, it stretches resources and execution capacity, and each area faces its own scientific, regulatory, and adoption risks. The long timelines and uncertainty typical of biotech and food‑tech innovation are important to keep in mind.

Summary

Pluri today looks like a classic high‑innovation, pre‑revenue platform company: scientifically and strategically ambitious, but financially thin and still in the build‑out stage. The income statement shows ongoing losses with no commercial revenue, the balance sheet has become weaker with negative equity, and cash flows are consistently negative, pointing to dependency on external funding. On the other side of the ledger, the company has a differentiated technology platform, a sizable IP portfolio, and is pursuing multiple promising markets—from cell therapies to cultivated foods and contract manufacturing. The main question is whether Pluri can secure enough time and capital to convert this innovation pipeline into durable, diversified revenue before financial constraints become too tight. Uncertainty is high, but so is the scope of potential outcomes, in both directions.